Beta Bionics (NASDAQ:BBNX) Chief Financial Officer Stephen Feider said the company's first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales ...
CEO Sean Saint opened the call by highlighting "strong performance in the third quarter" and updated annual projections for 2025. He cited record new patient starts and increased usage of the pharmacy ...
Net sales of $27.3 million, up 63% compared to $16.7 million in the third quarter of 2024. Gross margin of 55.5%, up 212 basis points compared to 53.4% in the third quarter of 2024. Installed customer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results